Limits...
Fully integrated biochip platforms for advanced healthcare.

Carrara S, Ghoreishizadeh S, Olivo J, Taurino I, Baj-Rossi C, Cavallini A, de Beeck MO, Dehollain C, Burleson W, Moussy FG, Guiseppi-Elie A, De Micheli G - Sensors (Basel) (2012)

Bottom Line: However, several issues have to be considered in order to succeed in developing fully integrated and minimally invasive implantable devices.Recent advances in the field have already proposed possible solutions for several of these issues.The aim of the present paper is to present a broad spectrum of recent results and to propose future directions of development in order to obtain fully implantable systems for the continuous monitoring of the human metabolism in advanced healthcare applications.

View Article: PubMed Central - PubMed

Affiliation: École Polytechnique Fédérale de Lausanne (EPFL), CH-1015 Lausanne, Switzerland. sandro.carrara@epfl.ch

ABSTRACT
Recent advances in microelectronics and biosensors are enabling developments of innovative biochips for advanced healthcare by providing fully integrated platforms for continuous monitoring of a large set of human disease biomarkers. Continuous monitoring of several human metabolites can be addressed by using fully integrated and minimally invasive devices located in the sub-cutis, typically in the peritoneal region. This extends the techniques of continuous monitoring of glucose currently being pursued with diabetic patients. However, several issues have to be considered in order to succeed in developing fully integrated and minimally invasive implantable devices. These innovative devices require a high-degree of integration, minimal invasive surgery, long-term biocompatibility, security and privacy in data transmission, high reliability, high reproducibility, high specificity, low detection limit and high sensitivity. Recent advances in the field have already proposed possible solutions for several of these issues. The aim of the present paper is to present a broad spectrum of recent results and to propose future directions of development in order to obtain fully implantable systems for the continuous monitoring of the human metabolism in advanced healthcare applications.

Show MeSH

Related in: MedlinePlus

CVD growth of CNTs.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3472872&req=5

f8-sensors-12-11013: CVD growth of CNTs.

Mentions: Direct growth by Chemical Vapour Deposition (CVD), is one of the most used forms of growing CNTs. In CVD, a hydrocarbon gas with carbon atoms is provided for the CNT growth on metallic catalysts [165]. The catalyst can be introduced in a vapour phase or is present as a solid layer on the substrate on which CNTs have to grow (Figure 8). Typically, nanotubes are grown on semiconducting or usually insulating silicon, silicon dioxide, quartz. The whole setup is then placed in a quartz tube, maintained at atmospheric pressure in a flow furnace. The hydrocarbon gas mixture is passed over the quartz at high temperatures (500–1,000 °C). The gas catalytically decomposes over the metal particles (iron or nickel) at these temperatures. Compared with other methods of CNT production, CVD has been regarded as the most promising for industrial application. In particular, CVD is the preferred choice to grow patterned CNTs on metal catalyst particles or islands deposited on top of the substrates. These catalytic metals are seeded onto metallic tracks realized on a substrate through standard microfabrication techniques (standard UV photolithography, electron-beam evaporation, lift-off).


Fully integrated biochip platforms for advanced healthcare.

Carrara S, Ghoreishizadeh S, Olivo J, Taurino I, Baj-Rossi C, Cavallini A, de Beeck MO, Dehollain C, Burleson W, Moussy FG, Guiseppi-Elie A, De Micheli G - Sensors (Basel) (2012)

CVD growth of CNTs.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3472872&req=5

f8-sensors-12-11013: CVD growth of CNTs.
Mentions: Direct growth by Chemical Vapour Deposition (CVD), is one of the most used forms of growing CNTs. In CVD, a hydrocarbon gas with carbon atoms is provided for the CNT growth on metallic catalysts [165]. The catalyst can be introduced in a vapour phase or is present as a solid layer on the substrate on which CNTs have to grow (Figure 8). Typically, nanotubes are grown on semiconducting or usually insulating silicon, silicon dioxide, quartz. The whole setup is then placed in a quartz tube, maintained at atmospheric pressure in a flow furnace. The hydrocarbon gas mixture is passed over the quartz at high temperatures (500–1,000 °C). The gas catalytically decomposes over the metal particles (iron or nickel) at these temperatures. Compared with other methods of CNT production, CVD has been regarded as the most promising for industrial application. In particular, CVD is the preferred choice to grow patterned CNTs on metal catalyst particles or islands deposited on top of the substrates. These catalytic metals are seeded onto metallic tracks realized on a substrate through standard microfabrication techniques (standard UV photolithography, electron-beam evaporation, lift-off).

Bottom Line: However, several issues have to be considered in order to succeed in developing fully integrated and minimally invasive implantable devices.Recent advances in the field have already proposed possible solutions for several of these issues.The aim of the present paper is to present a broad spectrum of recent results and to propose future directions of development in order to obtain fully implantable systems for the continuous monitoring of the human metabolism in advanced healthcare applications.

View Article: PubMed Central - PubMed

Affiliation: École Polytechnique Fédérale de Lausanne (EPFL), CH-1015 Lausanne, Switzerland. sandro.carrara@epfl.ch

ABSTRACT
Recent advances in microelectronics and biosensors are enabling developments of innovative biochips for advanced healthcare by providing fully integrated platforms for continuous monitoring of a large set of human disease biomarkers. Continuous monitoring of several human metabolites can be addressed by using fully integrated and minimally invasive devices located in the sub-cutis, typically in the peritoneal region. This extends the techniques of continuous monitoring of glucose currently being pursued with diabetic patients. However, several issues have to be considered in order to succeed in developing fully integrated and minimally invasive implantable devices. These innovative devices require a high-degree of integration, minimal invasive surgery, long-term biocompatibility, security and privacy in data transmission, high reliability, high reproducibility, high specificity, low detection limit and high sensitivity. Recent advances in the field have already proposed possible solutions for several of these issues. The aim of the present paper is to present a broad spectrum of recent results and to propose future directions of development in order to obtain fully implantable systems for the continuous monitoring of the human metabolism in advanced healthcare applications.

Show MeSH
Related in: MedlinePlus